BPC-157
| Category | Healing & Recovery |
| Goals | Joint & Tendon Repair · Gut Health · Recovery |
| Evidence level | Preclinical (mostly rodent; no large human trials) |
| Legal status | Research-only — not approved for human use |
| FDA status | Not approved; 503A Category 2 (no compounding); PCAC review Jul 23–24, 2026 |
| Half-life | Short (~minutes in animal data); human PK not well characterized |
| Routes | Subcutaneous · Oral · Intramuscular |
| CAS / MW / Sequence | 137525-51-0 · 1419.5 g/mol · GEPPPGKPADDAGLV (15 aa) |
| Last reviewed | 2026-06-07 |
In one line
A synthetic 15-amino-acid peptide derived from a protein in gastric juice, studied mainly in animals for tendon, ligament, muscle, and gut healing.
Evidence at a glance
The vast majority of BPC-157 data comes from rodent studies, much of it from a single research lineage. There are no completed large-scale human clinical trials for its popular uses. Treat human-use claims with caution. See Evidence Grading Explained and the Disclaimer.
Key Takeaways
- A stable synthetic pentadecapeptide designed to survive gastric acid.
- Best known for soft-tissue repair (tendon/ligament/muscle) and gut protection — but the strong evidence is animal-only.
- Mechanisms (angiogenesis, NO pathway, growth-factor signaling) are largely theorized from animal models; no clearly established human receptor target.
- Not FDA-approved; sold as a research chemical and currently under FDA compounding review.
- Most commonly paired with TB-500 (see the Wolverine Stack).
What Is It
BPC-157 (“Body Protection Compound 157”) is a synthetic, stable pentadecapeptide — a chain of 15 amino acids whose sequence derives from a partial sequence of a protective protein (BPC) found in human gastric juice. It does not occur naturally in this exact form; it was engineered to be stable in stomach acid, which is part of why oral use is discussed. It is best known in recovery and fitness communities for claimed acceleration of soft-tissue healing and protective effects on the gut.
Mechanism of Action
Mechanisms are largely theorized from animal models rather than confirmed in humans:
- Angiogenesis (animal evidence) — promotes new blood-vessel formation, partly via VEGFR2–Akt–eNOS signaling, which could support tissue repair.
- Nitric oxide (NO) system modulation (animal evidence) — interacts with the NO pathway, proposed to underlie vascular/cytoprotective effects.
- Growth-factor / FAK–paxillin signaling (animal/in-vitro) — proposed to influence tendon fibroblast outgrowth and migration.
- Gut cytoprotection (animal evidence) — protects gastric and intestinal mucosa in rodent injury models; this is the original research context.
Limitations
Many proposed mechanisms originate from the same research group and are not broadly independently replicated. The molecular receptor/target is not clearly established.
Evidence by Outcome
| Outcome | Evidence | Notes |
|---|---|---|
| Tendon / ligament healing | Preclinical | Accelerated healing in rat models; no human RCTs |
| Muscle injury recovery | Preclinical | Improved healing of crushed/transected muscle in rodents |
| GI protection (ulcers, IBD-like) | Preclinical | Original research context; strong in animals |
| NSAID-induced damage protection | Preclinical | Animal models |
| General “everything heals faster” | Anecdotal | Widely reported; no controlled human data |
| Neuroprotection / mood | Preclinical / Anecdotal | Preliminary rodent findings; no human evidence |
Reported Dosing
Not medical advice
Protocols as reported in community sources and non-clinical literature. There is no established human therapeutic dose. See Reconstitution & Dosing Math.
| Route | Dose (reported) | Frequency | Cycle |
|---|---|---|---|
| Subcutaneous | ~200–500 µg/day | 1–2× daily | ~2–6 weeks around an injury |
| Intramuscular | ~200–500 µg/day, near injury site | 1–2× daily | ~2–6 weeks |
| Oral | Reported for gut goals (acid-stable) | 1–2× daily | Variable |
Pharmacokinetics
Reported short half-life (minutes in some animal data), which is part of why frequent dosing is described anecdotally. Designed to be stable in gastric acid, distinguishing it from many peptides destroyed orally. Human PK is not well characterized. See Half-Life & Pharmacokinetics.
Side Effects & Risks
- Human safety data is essentially absent for chronic use — the central risk. “No reported side effects” reflects a lack of studies, not proven safety.
- Anecdotal reports: injection-site irritation, fatigue, lightheadedness, nausea — not systematically documented.
- Theoretical concern: because it promotes angiogenesis, there is speculative concern about effects on tumor growth; not adequately studied in humans.
- Sourcing risk: as a research chemical, identity/purity vary widely — see Sourcing and Red Flags & Scams.
- See Side Effects & Risk Management.
Cycling
Anecdotal protocols run BPC-157 for 2–6 weeks around an acute injury, then stop. No evidence-based cycling standard exists. See Cycling.
Stacks It Appears In
- Wolverine Stack — BPC-157 + TB-500 (the most-searched repair blend)
- GLOW / KLOW — skin/healing blends that include BPC-157
Comparisons
Sourcing & Quality
Sold almost exclusively as a lyophilized “research chemical,” so identity and purity are not guaranteed. Learn to evaluate quality before trusting a product: How to Read a CoA, HPLC vs Mass Spec, Third-Party Testing, Red Flags & Scams. Reconstitution and storage: Reconstitution & Dosing Math, Storage & Handling. No vendors are endorsed here.
Legal & Regulatory Status
(As of 2026-06-07.) Not FDA-approved for human use. The FDA placed BPC-157 in Category 2 of its interim 503A bulk-substances review (substances raising significant safety concerns), meaning compounding pharmacies cannot legally compound it for human use. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to discuss BPC-157 (free base and acetate) for potential inclusion on the 503A Bulks List on July 23, 2026 (the use FDA evaluated is ulcerative colitis; public docket FDA-2025-N-6895). Inclusion would only determine eligibility for traditional (503A) compounding — it is not drug approval. (Note: FDA’s January 2025 final interim guidance retired the Category 2/3 labels for substances nominated after Jan 7, 2025; BPC-157’s pre-existing Category 2 status and the pending PCAC review stand.) Status varies by country and may be prohibited in tested sport. See Regulatory & Legal Status.
FAQ
Is BPC-157 FDA-approved? No. It is not approved for human use. The FDA placed it in 503A Category 2 (compounding not permitted), and a PCAC advisory-committee review is scheduled for July 23–24, 2026.
Can a compounding pharmacy legally make BPC-157? No. Its 503A Category 2 status means it is not eligible for traditional (503A) compounding. Material sold online as “research” BPC-157 is outside this framework and unverified.
Is BPC-157 a steroid? No. BPC-157 is a peptide (a 15-amino-acid chain derived from a gastric protein), not an anabolic-androgenic steroid. It does not bind androgen receptors or build muscle the way steroids do; its studied effects are about tissue healing, and even those are largely preclinical (animal) — see below.
Does BPC-157 work in humans? The healing evidence is almost entirely from animal studies. Human data is minimal; popular claims are largely extrapolation and anecdote.
How long does BPC-157 take to work? There is no established human timeline — controlled human efficacy trials don’t exist, so any specific “X weeks” figure is anecdotal, not evidence-based.
Oral or injection? It is unusually acid-stable, so oral use is discussed (especially for gut goals); subcutaneous injection is most common for systemic/soft-tissue goals.
What is it usually stacked with? Most often TB-500 — see the Wolverine Stack.
References
- Sikiric P. et al. — reviews on BPC-157 and gut/tissue healing (e.g. Current Pharmaceutical Design; J. Physiology-Paris). Much primary work originates from this group.
- Chang C-H. et al. (2011). “The promoting effect of pentadecapeptide BPC 157 on tendon healing…” Journal of Applied Physiology.
- Gwyer D., Wragg N.M., Wilson S.L. (2019). “Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing.” Cell and Tissue Research.
- U.S. FDA. “Bulk Drug Substances Used in Compounding Under Section 503A” — BPC-157 (Category 2). fda.gov
- U.S. FDA (2026). “July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee” (agenda includes BPC-157 free base/acetate). fda.gov
← Healing & Recovery · Home Educational information only — not medical advice. See Disclaimer.